Weight-loss drugs may be helping lower US obesity, but experts say they aren't enough
A 2026 JAMA summit report credits GLP-1 drugs with a possible role in falling US obesity, then argues food, access and stigma decide whether it lasts.

The new class of weight-loss drugs may already be helping to bring down obesity rates in the United States, according to the 2026 JAMA Summit Report on Obesity. Its authors argue that the medicines alone won't keep the trend going.
The report looks at obesity as a global problem that now affects more than 1 billion people. It examines the biological, socioeconomic and environmental forces behind that number. Its main message for the US is a split verdict. GLP-1 receptor agonists, the drug class behind the recent boom in medical weight loss, could be one reason fewer Americans have obesity. But lasting progress, the authors contend, depends on healthier food environments, fair access to health care, less weight stigma and treatment tailored to the individual.
A cautious claim about the drugs
The wording of the drug finding deserves attention. The authors suggest the medications may be contributing to declining prevalence. They do not say the drugs have been shown to cause it. Population obesity rates move for many reasons, and a decline that lines up with rising prescriptions is not the same as proof that the prescriptions produced it. Treating the link as a plausible contributor, not a settled explanation, is the right call.
GLP-1 drugs mimic a gut hormone that helps regulate appetite and blood sugar. Semaglutide, sold as Ozempic for type 2 diabetes and as Wegovy for weight management, made the class a household name. Tirzepatide, marketed as Mounjaro and Zepbound, acts on GLP-1 along with a second hormone pathway. In clinical trials these drugs produced far more weight loss than earlier medications. That record explains why experts now take seriously the idea that they could affect national statistics, not just individual patients.
Why the report looks beyond medication
The authors' insistence on the wider picture rests on a well-documented limitation of the drugs. Studies have found that many people regain much of the lost weight after stopping treatment. That means the medicines work more like ongoing management than a cure. A national decline built mainly on prescriptions would hold only as long as large numbers of people can get the drugs, afford them and stay on them.
That is where the report's other priorities come in. Equitable access is the most immediate. Cost and uneven insurance coverage have shaped who has received GLP-1 drugs since demand took off. If the benefits flow mainly to people with good coverage, any drop in obesity could widen existing health gaps rather than close them.
The call for healthier food environments targets the conditions that drive weight gain to begin with, such as what food is cheap, convenient and heavily marketed. The focus on stigma reflects a long-standing concern in obesity medicine. Treating weight as a personal failing can discourage people from seeking care and can color how clinicians respond to them.
Personalized treatment is the report's final pillar. It points to a reality that one-size-fits-all approaches have struggled with. People gain weight for different reasons, and they respond differently to drugs, diet changes and surgery.
The report's framing is persuasive. After decades of rising obesity rates, a downturn of any size is genuinely good news, and it is tempting to hand the credit to a few blockbuster drugs. The summit authors push against that shortcut, arguing that lasting progress takes more than medication. That reasoning holds up: drugs treat obesity in people who already have it, while food environments, access and attitudes plausibly shape how many people develop it in the first place. A durable decline will likely need both.
The open question is whether the policy and public-health side of that agenda can move anywhere near as fast as the prescriptions have. For now, the authors frame the drugs' role as a possible contribution, not a proven one.




